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Background: Currently, a licensed vaccine for Dengue Virus (DENV) is not yet available. Virus-like particles (VLP)
have shown considerable promise for use as vaccines and have many advantages compared to many other types
of viral vaccines. VLPs have been found to have high immunogenic potencies, providing protection against various
pathogens.
Results: In the current study, four DENV-VLP serotypes were successfully expressed in Pichia pastoris, based on
co-expression of the prM and E proteins. The effects of a tetravalent VLP vaccine were also examined. Immunization
with purified, recombinant, tetravalent DENV1-4 VLPs induced specific antibodies against all DENV1-4 antigens in
mice. The antibody titers were higher after immunization with the tetravalent VLP vaccine compared to titers after
immunization with any of the dengue serotype VLPs alone. Indirect immunofluorescence assay (IFA) results indicated
that sera from VLP immunized mice recognized the native viral antigens. TNF-α and IL-10 were significantly higher in
mice immunized with tetravalent DENV-VLP compared to those mice received PBS. The tetravalent VLP appeared to
stimulate neutralizing antibodies against each viral serotype, as shown by PRNT50 analysis (1:32 against DENV1 and 2,
and 1:16 against DENV3 and 4). The highest titers with the tetravalent VLP vaccine were still a little lower than the
monovalent VLP against the corresponding serotype. The protection rates of tetravalent DENV-VLP immune sera
against challenges with DENV1 to 4 serotypes in suckling mice were 77, 92, 100, and 100%, respectively, indicating
greater protective efficacy compared with monovalent immune sera.
Conclusions: Our results provide an important basis for the development of the dengue VLP as a promising
non-infectious candidate vaccine for dengue infection.
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Dengue virus (DENV), a mosquito-borne RNA virus,
belonged to the genus Flavivirus of the family Flaviviridae,
is the cause of a range of well described clinical diseases,
dengue fever (DF), dengue shock syndrome (DSS) and
dengue hemorrhagic fever (DHF) [1,2]. Globally, over 2.5
billion people are at risk for DENV infection in tropical
and subtropical countries and regions, and approximately* Correspondence: jianglf909@163.com
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500,000 cases of DHF and/or DSS occur annually [3]. Pre-
vention and control of widespread dengue infection has
been a priority of the World Health Organization (WHO)
for three decades; however, a licensed vaccine for DENV
is not yet available [4].
There are four antigenically distinct serotypes of DENV,
designated as DENV1-4. Dengue fever can be caused by
any one of these four serotypes and life-long immunity
against a distinct serotype can be established after infec-
tion. However, the severe forms of DENV infection, DHF
and DSS, often occur when individuals are infected a sec-
ond time by a different serotype [5-7]. The increaseds is an Open Access article distributed under the terms of the Creative Commons
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at least in part, from antibody-dependent enhancement
(ADE) of DENV infection, in which antibody-mediated
neutralization does not occur. Instead, virus-antibody com-
plexes facilitate viral entry into cells that express the Fcγ
receptor, such as monocytes and macrophages [8-10]. For
these reasons, an effective dengue vaccine should be able
to induce long-lived protective immunity simultaneously
against all four DENV serotypes.
Three structural proteins (capsid (C), premembrane/
membrane (prM/M) and envelope (E)) and seven non-
structural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b
and NS5) are encoded in the RNA genome of the dengue
virus. The C protein forms the main structural component
of the nucleocapsid [11] and the formation of M, from
prM, appears to be the crucial, terminal event in virion
morphogenesis [12,13]. The E protein is located on the
surface of mature dengue virions and is the principal
glycosylated structural protein (MW 51,000 to 60,000).
The E protein mediates viral entry and induces a protect-
ive immune response [14-16]. The antibody response to
DENV infection is mainly directed against the E and prM
glycoproteins that are present on the virion surface
[17-19]. Antibodies have been found to both neutralize
and enhance DENV infectivity, in vivo and in vitro, and
thus appear to play a dual role in controlling DENV infec-
tion [10,20-24]. Presumably, this adverse association might
predict a potential risk for development of DHF or DSS in
an individual who had previously been vaccinated with a
specific DENV serotype and then is subsequently infected
with a different serotype. Indeed, the majority of DENV
vaccines under development are multivalent and aimed at
producing immunity potent enough to protect against all
four DENV serotypes [25].
Recent advances in genetic manipulation and vaccinol-
ogy have lead to renewed hope for the development of
live attenuated vaccines, subunit vaccines, DNA vaccines
and viral-vector vaccines. Of particular interest is the effort
to develop recombinant subunit vaccines, based on the
viral proteins, capable of mimicking the overall structure
of viral particles and inducing an optimal immune re-
sponse. To this end, the virus-like particles (VLP) approach
appears promising and advantageous over many other
structural forms of vaccines. VLPs have been found to pro-
vide high immunogenic potency in protecting against vari-
ous pathogens, such as human papillomavirus [26].
It has been demonstrated that co-expression of flavivirus
prM and E, or alternatively, C, prM, and E led to produc-
tion of VLPs that were composed of spherical membrane
vesicles containing prM/M and E embedded in a lipid
bilayer with or without a nucleocapsid, similar to the
morphology of natural virions. These VLPs showed im-
munogenicity and were able to elicit neutralizing anti-
bodies and virus-specific cytotoxic T lymphocytes [27-29].Our previous studies demonstrated that co-expression of
the prM and E proteins of DENV1, DENV2, and DENV3
produced antigenic DENV-VLP [30-32]. In the current
study, DENV4-VLP was constructed and expressed, and
the immunological properties and protection level of
tetravalent DENV-VLP were evaluated in mice challenged
with all four DENV serotypes. The data suggest that
antibody responses and cellular immunity induced by
monovalent and tetravalent DENV-VLP were compar-
able. Tetravalent DENV-VLP had better protective ef-
ficacy compared to monovalent VLP in suckling mice.
The results indicate that tetravalent DENV-VLP could
be a promising vaccine candidate.
Methods
Cells and viruses
C6/36 Aedes albopictus (ATCCNo.CRL-1660) was cultured
at 28°C in MEM (Gibco, Guangzhou, China) supplemented
with 0.11% of sodium bicarbonate and 10% newborn calf
serum (Gibico, USA). BHK-21 Mesocricetus auratus was
cultured in DMEM (Gibico, Guangzhou, China) supple-
mented with 10% fetal bovine serum (Gibco, USA) at 37°C in
5% CO2. Each dengue virus serotype was passaged and prop-
agated in C6/36 cells and titrated in BHK-21 cells. The
DENV1 strain, GZ01/95 (GenBank accession No. EF032590),
and DENV2 strain, ZS01/01 (GenBank accession no.
EF051521), had been previously isolated, sequence-verified
and preserved in our laboratory. DENV3 strain H87 and
DENV4 strain H241 were supplied by the Institute for
Viral Disease Control and Prevention, China CDC. The
viral titer was determined after removal of cell debris via
centrifugation. The virions used for mice immunization
were inactivated with 1:2000 β-propionolactone and the
viron concentration was subsequently detected using the
BCA method (Biocolor, Shanghai, China).
Construction of DENV-VLP expression plasmids
The P. pastois host strain, X33 (Invitrogen, Guangzhou,
China), and the expression vector, pGAPZαA (Invitrogen),
have been previously described in detail [30,31]. The
cDNA of virions of each DENV serotype was obtained
by RT-PCR and the genes coding for the prM and E pro-
teins were amplified. The amplified prM-E genes were
subsequently linearized and ligated into the pGAPZαA
(Invitrogen) vectors in frame with the α-factor secretion
signal (for DENV1/2-VLP expression) or the signal pep-
tide of prM (for DENV3/4-VLP espression). The re-
combinant plasmids for expressing DENV1-4 VLP were
named pGAPZα-prME-D1, pGAPZα-prME-D2, pGAPZ-
sprM/E-D3, and pGAPZ-sprM/E-D4.
Expression and purification of DENV-VLP
Expression and purification of DENV-VLP was done as
previously described [30-32]. Briefly, the four recombinant
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strain, X33. The yeast cells were then harvested and
disrupted with glass beads in breaking buffer (50 mmol/L
sodium phosphate, pH 7.4; 1 mmol/L ethylene diamine
tetraacetic acid (EDTA); 1 mmol/L phenylmethyl sulfonyl-
fluoride (PMSF); and 5% glycerol). The lysates were sub-
jected to ultracetrifugation at 153 000 × g for 6 hours
at 4°C (HATICHI, P80AT rotor, Ibaraki Prefecture, Japan)
using a 5 ~ 50% sucrose density gradient before the
sucrose fractions were collected and analyzed via Western
blot, using the MAb 15 F3-1 (ATCC, USA), 3H5-1
(ATCC, USA), 5D4-11 (ATCC, USA), and IH10-6 (ATCC,
USA) to detect E proteins expression for each DENV-VLP
serotype. The formation of VLP was demonstrated using
electron microscopy. Finally, protein concentration was
assessed using the BCA method (Biocolor, Shanghai,
China).
Virus titer assay
Virus quantitation was determined using a standard plaque
assay as previously described [30,31]. Briefly, 0.25 mL of
DENV dilutions (10-fold) was added to duplicate wells of
BHK-21 cells, which were cultured overnight in 24-well
plates before the media was removed. The plates were in-
cubated for 2 h after which the media was aspirated and
replaced with 0.8 mL of 0.8% methyl-cellulose medium
(with 4% newborn calf serum). The plates were then incu-
bated for 7 days, the media was removed and the cells were
fixed in 4% formaldehyde and stained with crystal violet.
Plaques were counted visually and the concentrations of
plaque-forming units per mL (PFU/mL) were calculated.
Mice immunization
Experiments with mice were conducted in compliance
with a protocol approved by the Institutional Animal Care
and Use Committee of Sun Yat-sent University based on
the Ethical Principles in Animal Experimentation. Specific
pathogen-free female BALB/c mice, aged three to four
weeks, were supplied by the Experimental Animal Center
of Sun Yat-sen University (Guangzhou, China) and were
divided into ten groups according to immunogen. The
mice were inoculated intraperitoneally (i.p.) with monova-
lent DENV-VLP (25 μg per dose and in 15 mice (n = 15))
of a specific serotype or a tetravalent combination (25 μg of
each serotype per dose and in 30 mice (n = 30)). Freund’s
complete adjuvant (Sigma) was used for priming and
Freund’s incomplete adjuvant was used for boosters. Boot-
ers were twice at an interval of 2 weeks. Equal amounts of
PBS (n = 30) or inactivated DENV virions (25 μg per
dose and in 15 mice (n = 15)) were used as controls. Blood
samples were collected on days 0, 14 and 28, via the tail
vein, for measurement of serum IgG. Seven days after
the last inoculation, 1/3 of the mice in each group were
euthanized. The spleen of each mouse was removed andsplenocytes were isolated in order to test cytokine pro-
files and serum was collected for further immunological
analysis.
Enzyme-linked immunosorbent assay
Antigen specific serum IgG antibodies were titered using
an amplified sandwich ELISA system. Briefly, 96 wells
polystyrene plates (Costar, USA) were coated over night
at 4°C with 100 μL/well of 5 ng/ml inactivated dengue
virus antigen or VLP antigen and then blocked in coat-
ing buffer containing 5% fat-free milk powder for 1 h at
37°C. The plates were then incubated with 100 μl/well of
sera from each group, along with a 2-fold serial dilution
of PBS-T (starting from 1:100), at 37°C for 1 h. Bound
IgG was detected using goat anti-mouse IgG-peroxidase
conjugate (Santa Cruz, USA). A volume of 3,3′, 5,5′-tet-
ramethly benzidine (TMB) substrate was then added and
plates were incubated at 37°C for 15 min. The reaction
was stopped with 50 μl of 2 M H2SO4. Absorbance was
measured at 450 nm using an automated ELISA reader
(EL×800 BioTek). An absorbance value two-fold above
the mean pre-vaccine serum value plus two standard de-
viations was considered to be a positive result.
Immunofluorescence assay
C6/36 cells were passaged in MEM medium containing
10% fatal bovine serum (FBS) and used to be infected
with 100 PFU of each DENV serotype. Cells were har-
vested 2 ~ 4 days post-infection, resuspended in MEM
containing 10% newborn calf serum, dropped onto slides
and incubated at 37°C for 8 h. The slides were then fixed
with acetone at −20°C for 15 min. Antisera diluted 1:80,
was then added to the slides and the slides were incubated
at 37°C for 1 h. Normal mouse sera, diluted 1:80, was used
as the negative control. Lastly, fluorescein isothiocyanate
(FITC)-conjugated goat anti-mouse IgG was added and
the slides were incubated at 37°C for 45 min. Positive cells
were detected using a fluorescent microscope.
Cytokines ELISPOT assay
The cytokines, IFN-γ, TNF-α, and IL-10, from immunized
mice were measured using ELISPOT kits (Ucytech, The
Netherlands), according to the manufacturer’s instruc-
tions. Briefly, ELISPOT 96-well plates (Millipore, USA)
were coated with 100 μl of anti-mouse IFN-γ, anti-mouse
IL-10, or anti-mouse TNF-α (5 μg/ml in coating buffer).
The plates were washed twice and blocked with blocking
solution for 2 h. A volume of 100 μL freshly isolated
splenocytes (2 × 105 cells) from the immunized mice
were subsequently transferred to each well and stimu-
lated with dengue virus at 37°C for 24 h. The cells were
then washed away, and a secondary biotinylated anti-
cytokine mAb was added to each well, followed by a
streptavidin-HRP and AEC substrate solution system.
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Analyzer (Cellular Technology Ltd. USA).
Antibody neutralization assay
The neutralizing ability of antibodies was measured using
a 50% plaque reduction neutralization test (PRNT50).
Briefly, BHK-21 cells were grown to 80% confluence in 24-
well plates and infected with 200 μL DENV1 to 4 (150 ~
200 PFU/mL). The plates were then pre-incubated with
two-fold serial dilutions of mouse serum (1:4 ~ 1:64) at
37°C for 1 h. The virus-serum mixture was aspirated,
added along with 0.8 mL overlay medium, and incubated
at 37°C with 5% CO2 for 7 days. Dengue virus plaques
were counted by naked eye or by scanning the cluster
plate into Adobe Photoshop CS for further magnification.
PRNT50 titers are defined as the maximal serum dilution
that inhibits 50% of plaque formation compared to the
number of plaques in infected cell wells with no sera.
Suckling mice passive protection assay
Newborn (1 day old) BALB/c mice were purchased from
the Experimental Animal Center of Sun Yat-sen University
(Guangzhou, China) and were divided into twelve groups.
The 1:10 sera dilution was incubated with each DENV
serotype (400PFU) at 37°C for 1 h. Suckling mice were
injected intracerebrally with 20 μL of sera-virus mixture.
Morbidity (paralysis, ruffling, slowing of activity, kyphos-
coliosis and death) and/or mortality were recorded daily,
for 3 weeks, post-challenge in all mice.Figure 1 Secretion analysis of DENV4 VLPs. (A) SDS-PAGE analysis of di
Sucrose gradient sedimentation and SDS-PAGE analysis of DENV4 VLP secre
sucrose density gradient ultracentrifugation and different fractions were co
5: 25%; 6: 30%; 7: 35%; 8: 40%; 9: 45%; 10: 50%. (B) Western Blot analysis of
density gradient ultracentrifugation were analyzed for E protein expression
antigen. The size of the molecular weight marker is shown in kDa.Statistical analysis
Data were analyzed for statistical significance using SPSS
software (version 13.0). Statistical comparisons among
groups were analyzed by one way ANOVA. Kaplan-Meier
survival curves used for survival analysis and were ana-
lyzed by the log rank test.
Results
Expression and purification of DENV-VLP
Yeast lysates were analyzed for expression of E proteins
by Western blot using mAbs as described in Methods.
A ~50 kDa recombinant E protein band was detected
in the lysates of each DENV-VLP expression clones
[30-32] (Figure 1A). The lysates of yeast cells express-
ing DENV1 to 4 VLPs were analyzed using a 5 ~ 50%
sucrose density gradient centrifugation. Western blot
results indicated that DENV-VLP was present in the fac-
tion 20% ~ 25% [30-32] (Figure 1B). The spherical particles
with diameters of about 30 nm were detected by electron
microsopy [30-32] (data not shown). After the fractions
containing VLP were harvested and mixed, the recombin-
ant protein concentration was adjusted to 0.5 mg/mL,
then aliquoted and stored −80°C.
Immunogenicity of purified tetravalent DENV-VLP
Purified, recombinant, tetravalent DENV1-4 VLP anti-
gen was tested for the ability to induce specific anti-
bodies against each DENV1-4 VLP antigen in mice via
ELISA. Antibody titers were higher after immunizationfferent fractions from sucrose density gradient ultracentrifugation.
tions. The pGAPZaA-sprME-D4-X33 yeast lysates were centrifuged by
llected and analyzed by SDS-PAGE. 1: Marker; 2: 10%; 3: 15%; 4: 20%;
E protein expression. The 20 ~ 25% fractions collected from sucrose
using the MAb IH10-6 (anti-DENV4 E protein). Arrows indicate E
Figure 2 (See legend on next page.)
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Figure 2 Indirect ELISA analysis of Dengue Virus or VLP specific IgG antibody. BALB/c mice were intraperitoneally immunized with 25 μg
monovalent DENV1-4 VLP, DENV1-4 virions, or tetravalent combination (25 μg of each serotype) a total of three times at two-week intervals. Sera
were collected on days 0, 13, 27, and 34 and indirect ELISA was used to test for antigen specific IgG. Sera from monovalent VLP groups and the
tetravalent VLP group reacted with DENV1-4 VLP antigens and sera from inactivated DENV groups reacted with dengue virus 1–4 antigens. Data
are expressed as mean absorbance at OD450 nm with a standard error of the mean (SEM) bar. The baseline (dashed line) indicates negative
values with normal mouse serum. A. Binding of sera from mice immunized with DENV1-VLP and inactivated DENV1 virions to respective antigens;
B. Binding of sera from mice immunized with DENV2-VLP and inactivated DENV2 virions to respective antigens; C. Binding of sera from mice
immunized with DENV3-VLP and inactivated DENV3 virions to respective antigens; D. Binding of sera from mice immunized with DENV4-VLP
and inactivated DENV4 virions to respective antigens; 0045. Binding of sera from mice immunized with tetravalent VLP to respective antigens.
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immunization with any of the the monovalent serotype
dengue VLPs (Figure 2). Indirect immunofluorescence
assay (IFA) results showed that serum from mice immu-
nized with either monovalent or tetravalent VLPs recog-
nized homologous viral antigens (Figure 3). The antibody
titers ranged from 1:320 to 1:640 and the titers from the
group immunized with tetravalent VLPs were higher than
any of the corresponding antibody titers from the groups
immunized with monovalent VLPs. These results indi-
cate that immunization with tetravalent VLPs induced
stronger antibody responses than immunized with mono-
valent VLPs.
Cytokine production measured by ELISPOT
Spleen cells were isolated on day 34 (7 days after the last
immunization) to assess the cellular immune response
to tetravalent DENV VLP. IFN-γ, TNF-α, and IL-10
cytokine secretion was analyzed, via ELISPOT, following
their ex vivo stimulation of the cells with inactivated
DENV1-4 virions.
As shown in Figure 4, there was no significant differ-
ence in the number of splenocytes secreting IFN-γ fromFigure 3 Indirect immunofluorescence detected that sera from
tetravalent VLPs recognized DENV antigens. The C6/36 cells
infected with DENV1-4 were fixed, incubated with a 1:40 dilution of
antisera from the tetravalent VLP group and then stained for the
virus (green). Evens blue dye staining was used to label cells (red).
Magnification 400 × .animals immunized with tetravalent DENV VLP com-
pared to PBS control, after stimulation with all four den-
gue serotype virions. The number of splenocytes secreting
TNF-α was higher in the tetravalent DENV VLP group
compared to the control group and the number of spleno-
cytes secreting TNF-α was higher after stimulation with
DENV1 or 2 virions than with DENV3 or 4 virions. The
overall number of IL-10 secreting cells was not high in
tetravalent DENV VLP group, however, the mean number
of cells secreting IL-10 was significantly higher in this
group after stimulation with DENV3 or 4 virions com-
pared to the PBS control group. Conversely, there was no
significant difference in IL-10 secreting cells between the
teravalent DENV-VLP and control groups after stimula-
tion with DENV1 or 2 virions.
Virus neutralizing antibodies induced by DENV-VLP in
mice
Virus neutralizing antibody responses to the homologous
serotypes were determined by PRNT50 analysis of mouse
sera in order to evaluate the effective humoral immune re-
sponse induced by DENV-VLP. The maximum neutralizing
antibody titer of the DENV1-VLP group was equivalent to
that of the inactivated DENV1 group (Figure 5). The max-
imum neutralizing antibody titer in the DENV2-VLP
group was 1:64, which was higher than the 1:32 titer in
the inactivated DENV2 group. Though the maximum titer
in both the DENV3-VLP and inactivated DENV3 groups
was 1:32, the% plaque reduction was slightly lower in
the DENV3-VLP group than in the inactivated DENV3
group. The maximum titer was 1:32 in DENV4-VLP
group and 1:8 in inactivated DENV4 group. In summary,
the maximum neutralizing antibody titer was the highest
in DENV2-VLP group and titers were higher in groups
that received VLP than in groups that received inactivated
virions, except in the case of DENV3 where titers in the
VLP and inactivated groups were the same.
PRNT50 titers induced by tetravalent VLP immunization
against each viral serotype were determined in order to
demonstrate that monovalent VLP could be combined to
produce an effective tetravalent formulation that elicits
neutralizing antibodies against all four dengue serotypes.
Tetravalent VLP stimulated neutralizing antibodies against
Figure 4 ELISPOT assay. The mice immunized with tetravalent DENV-VLP were euthanized 7 days after the 3rd immunization and the spleen
cells were isolated and stimulated in vitro with inactivated virions of each DENV type. IFN-γ (A), TNF-α (B), and IL-10 (C) producing lymphocytes
were enumerated by ELISPOT assay. The mean number of spot forming cells (SFCs)/2 × 105 (splenocytes) is shown as virions-stimulated
with an SEM bar. *indicates statistical significance (*P < 0.05; **P < 0.01).
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against DENV3 and 4) (Figure 6). The highest titers were
a little lower than those induced by immunization with
the corresponding monovalent VLP.
Protection of suckling mice from viral challenge
Protection induced by monovalent or tetravalent dengue
VLPs, in virally challenged suckling mice, was also tested.
Control mice challenged with DENV1 began to get sick
on day 6, some died on day 7 and all died by day 11. Mice
that received anti-DENV1-VLP sera began to get sick on
day 8, some died on day 10 and all died by day 15. The dif-
ferences in morbidity and survival rates were statistically
significant between the 2 groups. Control mice challenged
with DENV2 began to get sick and die on day 8 and all
died by day 11, while the mice that received anti-DENV2-
VLP sera began to get sick on day 6, some died on day 8
and two mice (2/10) were still alive on day 21. However,
the differences in morbidity and survival rates were not
significant between these 2 groups. Control mice chal-
lenged with DENV3 began to get sick on day 7, some died
on day 8 and all died by day 12, while mice that received
anti-DENV3-VLP sera began to get sick on day 8, some
died on day 9 and one mouse (1/14) was still alive on day
21. The differences in morbidity and survival rates were
statistically significant between these 2 groups. Control
mice challenged with DENV4 began to get sick on day 3,
some died on day 4 and all died by day 9, while micethat received anti-DENV4-VLP sera began to get sick
on day 4, some died on day 6 and three mice (3/12)
were still alive on day 21. The differences in morbidity
and survival rates were statistically significant between
these 2 groups (Figure 7).
Mice in the anti-tetravalent-VLP sera group that were
challenged with DENV1 began to get sick on day 9, and
some died on day 10, however there were still 10 mice
(10/13) alive on day 21. Mice in the anti-tetravalent-VLP
sera group that were challenged with DENV2 began to get
sick on day 7, and some died on day 10, however there
were still 11 mice (11/12) alive on day 21. None of the
mice in the anti-tetravalent-VLP sera group got sick or
died by day 21 after DENV3 or DENV4 challenge. Al-
though 2 mice in the anti-tetravalent-VLP sera group that
were challenged with DENV4 died on day 1, there were
no mice got sick or died until day 21. Considering the 2
mice were accidental die, the protection rates against the
four DENV serotypes were 77, 92, 100, and 100%, respect-
ively (Figure 8).
Discussion
VLPs have similar structural and physicochemical features
to infectious virions, however they are non-infectious and
have advantages in terms of safety and manufacturing. An
important characteristic of VLPs is that they can elicit
strong humoral and cellular immune responses against
viruses [33-35]. Recombinant flaviviruses VLPs have
Figure 5 Detection of monovalent immune serum neutralizing antibody against DENV. Balb/c mice were immunized with 25 μg monovalent
DENV VLP or virions a total of three times at a two week interval. On day 7 after the 3rd immunization, neutralizing antibodies against DENV1
(A), DENV2 (B), DENV3 (C), and DENV4 (D) were assessed using a PRNT50 assay. 150-200PFU DENV were incubated with serially diluted
mouse antisera in 24-well plates, using BHK-21 cell lines. Data from each group is expressed as the mean percentage of plaque reduction
with an SD bar (n = 3). The PRNT50 titers for each immune sera after immunization with each monovalent vaccine against the corresponding
virus were 1:32, 1:64, 1:32, and 1:32, respectively. *indicates statistical significance (*P < 0.05; **P < 0.01).
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expression of prM and E proteins, either with or without
C proteins [36,37]. Our previous study demonstrated that
DENV-VLP could be successfully expressed in Pichia
pastoris, based on co-expression of prM and E proteins
[30-32]. In that study, it was shown that vaccination with
DENV-VLP efficiently elicited virus-specific humoral and
cellular immune responses in BALB/c mice. In the current
study, the immunogenicity and protective effect of a vac-
cine made up of four DENV-VLP serotypes was evaluated.
The analysis of humoral immune responses revealed
that each of the four dengue VLP serotypes induced anti-
gen specific IgG, similar to the corresponding inactivated
dengue virions. The antibody levels were higher in
DENV1 and 2-VLP vaccinated groups than in the DENV3
and 4-VLP groups and in the tetravalent VLP vaccinated
group than in monovalent groups. Indirect immunofluor-
escence assay results showed that the antisera from the
dengue VLP vaccinated groups could bind with natural
dengue virus antigen. In addition, cross-reactions were
found between the immune sera from the four DENV-VLP serotypes and the natural DENV virions (data not
shown). The results suggest that joint immunization with
polyvalent antigens may have a synergistic effect in stimu-
lation of the antibody production.
VLPs not only induce antibody production, but they
also have the ability to induce cellular immunity [38,39].
In the present study, cellular immune responses were
assessed by the ability of VLPs-stimulated spleen cells to
release IFN-γ, TNF-α, and IL-10 cytokines. The number
of TNF-α and IL-10 secreting splenocytes was signifi-
cantly higher in mice that received tetravalent DENV-
VLP compared to PBS controls. However, neither IFN-γ
nor TNF-α secreting splenocytes were significantly
higher in the monovalent DENV-VLP groups (data not
shown). IFN-γ is a type of Th1 cytokine, that has an
anti-viral effect and also enhances TNF-α production by
DENV-infected cells. In addition, high systemic levels of
TNF-α have been shown to cause capillary leakage [40].
Serum levels of TNF-α and its receptors have been
shown to be elevated in DENV infection and to correlate
with DENV disease severity [41,42]. In particular, it has
Figure 6 Detection of tetravalent immune serum neutralizing antibody against DENV. Balb/c mice were immunized with 100 μg tetravalent
DENV-VLP (total of 25 μg for each DENV-VLP serotype) a total of three times at a two week interval. Neutralizing antibodies against DENV1-4 were
assessed seven days after the 3rd immunization, using the PRNT50 assay. 150-200PFU DENV were incubated with serially diluted mouse antisera in
24-well plates, using BHK-21 cell lines. Data from each group is expressed as the mean percentage of plaque reduction with an SD bar (n = 3).
The PRNT50 titer of the tetravalent immune sera against the four DENV serotypes were 1:32, 1:32, 1:16, and 1:16, respectively. (A) the PRNT50 titer of
tetravalent immune serum; (B) the plaque morphology.
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type I IFN-mediated antiviral activity [43]. In addition
to the above three cytokines, many other cytokine/
chemokines are considered to be correlated with dengue
disease severity, including IL-1 β, IL-2, IL-6, IL-8, IL-10,
IL-13, IL-18, IFN-γ, TNF-α, and MCP1 [42,44-50]. Results
of the current study are not enough to evaluate Th1 or
Th2 immune responses produced by tetravalent DENV-
VLP or the corresponding dynamic variation. Further
studies of T-cell responses are needed to understand the
immune status of mice immunized with the tetravalent
DENV-VLP.
The protective efficacy of tetravalent DENV-VLP was
demonstrated with an antibody neutralization assayin vitro and in suckling mice in vivo. PRNT50 results
showed that immunization with either monovalent or
tetravalent DENV-VLP induced neutralization antibodies
against dengue virus. The PRNT50 titers from immune
sera of mice immunized with DENV1 and 2-VLP were
higher than titers from immune sera of mice immunized
with DENV3 and 4-VLP; however, these titers were all
higher than immune sera titers reported after immunization
with the tandem DENV1-4 domain III of the E protein [51]
and higher than the DENV1-4 VLP level expressed in
293 T cell immune sera [52]. The DENV-VLP in the present
study showed good immunogenicity and neutralization
efficacy, though there are still some differences in ef-
ficacy among the four DENV serotypes. The PRNT50
Figure 7 Protective assay in suckling mice. Protective effects of monovalent mouse antisera were evaluated in suckling mice. Suckling mice
were intracerebrally inoculated with DENV1, 2, 3, or 4, and clinical signs of infection, mainly hind leg paralysis, alterations in spinal column and
mortality, were monitored for 21 days. (A) survival curve; (B) mobidity curve. Different letters mean statistically significant differences by the
Log-rank test. *indicates statistical significance (*P < 0.05; **P < 0.01).
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lent DENV-VLP were a little lower than those from mice
immunized with the corresponding monovalent DENV-
VLP. Since the antibody levels detected by ELISA and
IFA were also higher in the tetravalent VLP group than
in the monovalent groups, we deduced that there was
no significant relationship between antibody level and
neutralization efficacy, particularly since more non-neutralizing antibody against a certain dengue serotype
might exist in the tetravalent DENV-VLP immune sera.
The protective efficacy of the tetravalent DENV-VLP
vaccine candidate was further tested in a suckling mouse
model. The results showed that immunization with either
monovalent or tetravalent DENV1-4 VLPs conferred at
least some protection, in suckling mice, against DENV1-4
challenge. Furthermore, although the neutralizing antibody
Figure 8 Anti-tetravalent VLP sera protective assay in suckling mice. Protective effects of mouse antisera from the tetravalent VLP group
were evaluated in suckling mice. Mice were intracerebrally inoculated with DENV1, 2, 3 or 4 and clinical signs of infection, mainly hind leg
paralysis, alterations in spinal column and mortality, were monitored for 21 days. (A) survival curve; (B) mobidity curve. Different letters mean
statistically significant differences by the Log-rank test. *indicates statistical significance (*P < 0.05; ** P < 0.01).
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of DENV1-4 VLP in vitro, the tetravalent formula pro-
vided more protective efficacy in vivo than did the mono-
valent vaccination. This suggests that the in vivo immune
response is more complex, and that in vivo protective effi-
cacy might be dependent on various immunologic mecha-
nisms and not just the neutralizing antibody. Moreover,
the tetravalent formula had better protective efficacy
against DENV3 and 4 compared to DENV1 or 2, suggest-
ing that further study of the compatibility of tetravalent
DENV1-4 VLP is needed.
Conclusions
In conclusion, the construction of a tetravalent DENV1-4
VLP vaccine candidate, based on Pichia pastoris, is de-
scribed. The tetravalent DENV-VLP induced humoral im-
mune responses against all four dengue virus serotypes asmeasured by ELISA or IFA and also induced cellular im-
munity. The antibody levels were higher, though the neu-
tralizing titers were somewhat lower with tetravalent than
with monovalent immunization. Moreover, protective effi-
cacy in the suckling mouse model was better with the
tetravalent than with the monovalent vaccination. Further
study is needed to adjust the compatibility of the tetrava-
lent DENV1-4 VLP formula and to clarify the amount of
cellular immunity that is induced.
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